Title: A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice.
Journal: Atherosclerosis 20140901
Title: RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain.
Journal: Proceedings of the National Academy of Sciences of the United States of America 20131203
Title: RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist.
Journal: PloS one 20130101
Title: ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies.
Journal: Cardiovascular drugs and therapy 20120401
Title: RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo.
Journal: Journal of the American College of Cardiology 20100608
Title: RVX-208, a stimulator of apolipoprotein AI gene expression for the treatment of cardiovascular diseases.
Journal: Current opinion in investigational drugs (London, England : 2000) 20100301
Title: Picaud S, et al. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc Natl Acad Sci U S A. 2013 Dec 3;110(49):19754-9.
Title: McLure KG, et al. RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist. PLoS One. 2013 Dec 31;8(12):e83190.
Title: Jahagirdar R, et al. A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice. Atherosclerosis. 2014 Sep;236(1):91-100.
